Elizabeth A Ward

US Patent:

7083784, Aug 1, 2006

Filed:

Dec 12, 2001

Appl. No.:

10/020354

Inventors:

William Dall'Acqua - Gaithersburg MD, US
Leslie S. Johnson - Germantown MD, US
Elizabeth Sally Ward - Dallas TX, US

Assignee:

MedImmune, Inc. - Gaithersburg MD

International Classification:

C07K 16/00
A61K 39/395
C12P 21/08
C12N 1/00

US Classification:

4241301, 5303871, 5303877, 5303879, 435810

Abstract:

The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

US Patent:

7670600, Mar 2, 2010

Filed:

Apr 3, 2006

Appl. No.:

11/397328

Inventors:

William Dall'Acqua - Gaithersburg MD, US
Leslie S. Johnson - Germantown MD, US
Elizabeth Sally Ward - Dallas TX, US

Assignee:

MedImmine, LLC - Gaithersburg MD
Board of Regents, The University of Texas System - Austin TX

International Classification:

C07K 16/00
A61K 39/395
C12P 21/08
C12N 1/00

US Classification:

4241301, 5303871, 5303877, 5303879, 435810

Abstract:

The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

US Patent:

7704497, Apr 27, 2010

Filed:

Jan 3, 2007

Appl. No.:

11/649455

Inventors:

William Dall'Acqua - Gaithersburg MD, US
Leslie S. Johnson - Darnstown MD, US
Elizabeth Sally Ward - Dallas TX, US

Assignee:

MedImmune, LLC - Gaithersburg MD
Board of Regents, The University of Texas System - Austin TX

International Classification:

C07K 16/00
A61K 39/395
C12P 21/08
C12N 1/00

US Classification:

4241301, 5303871, 5303877, 5303879, 435810

Abstract:

The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

US Patent:

8012476, Sep 6, 2011

Filed:

Jan 21, 2010

Appl. No.:

12/691433

Inventors:

William Dall'Acqua - Gaithersburg MD, US
Leslie S. Johnson - Germantown MD, US
Elizabeth Sally Ward - Dallas TX, US

Assignee:

MedImmune, LLC - Gaithersburg MD
Board of Regents, The University of Texas System - Austin TX

International Classification:

C07K 16/00
A61K 39/395
C12P 21/08
C12N 1/00

US Classification:

4241301, 5303871, 5303877, 5303879, 435810

Abstract:

The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

US Patent:

8323962, Dec 4, 2012

Filed:

Jul 27, 2011

Appl. No.:

13/192429

Inventors:

William Dall'Acqua - Gaithersburg MD, US
Leslie S. Johnson - Darnestown MD, US
Elizabeth Sally Ward - Dallas TX, US

Assignee:

MedImmune, LLC - Gaithersburg MD
Board of Regents, The University of Texas System - Austin TX

International Classification:

C07H 21/02
C07H 21/04
C12N 15/00

US Classification:

4353201, 536 231, 536 2353

Abstract:

The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

US Patent:

20130330328, Dec 12, 2013

Filed:

Nov 14, 2011

Appl. No.:

13/885219

Inventors:

Ronald Herbst - Gaithersburg MD, US
Elizabeth K. Ward - Gaithersburg MD, US
Kathleen Phillips McKeever - Gaithersburg MD, US

Assignee:

Medimmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395

US Classification:

4241331, 4241731

Abstract:

The present disclosure provides methods for treating B cell lymphomas using a combination of anti-CD19 and anti-CD20 antibodies. Such methods provide therapeutic advantages over single antibody therapies, including prolonged anti-tumor activity and/or reduced dosages.